Tags : Late-stage

Moderna to Commence Late-stage COVID-19 Vaccine Trial on 27 July,

Shots: Moderna has reported the robust results of its ongoing P-I study that demonstrated mRNA-1273 at (25-, 100- & 250-mcg dose levels) induced anti–SARS-CoV-2 immune responses in all participants with no trial-limiting safety concerns. These results were published in NEJM All participants seroconverted by the 15-day mark. Post two vaccinations, @57day, geometric mean titers exceeded […]Read More

GE Healthcare Signs a Worldwide Development and Commercialization Agreement with

Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer   The companies […]Read More